Login to Your Account



GIST data provide another potential Iclusig indication

By Peter Winter
BioWorld Insight Editor

Monday, June 2, 2014

Ariad Pharmaceuticals Inc. provided positive clinical data for Iclusig. The drug had a rocky start after receiving a December 2012 approval for use in patients with chronic, accelerated and blast phases of  CML and Ph+ ALL whose disease is resistant or intolerant to tyrosine kinase inhibitors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription